Santhera Pharmaceuticals Holding AG
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SPHDF research report →
Companywww.santhera.com
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies.
- CEO
- Dario Eklund
- IPO
- 2014
- Employees
- 78
- HQ
- Pratteln, CH
Price Chart
Valuation
- Market Cap
- $337.73M
- P/E
- -4.63
- P/S
- 3.20
- P/B
- -19.29
- EV/EBITDA
- -10.53
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 18.74%
- Op Margin
- -48.99%
- Net Margin
- -63.79%
- ROE
- 684.83%
- ROIC
- -34.49%
Growth & Income
- Revenue
- $77.22M · 97.41%
- Net Income
- $-49,259,603 · -17.36%
- EPS
- $-3.78 · -2.44%
- Op Income
- $-37,834,129
- FCF YoY
- 2.37%
Performance & Tape
- 52W High
- $23.25
- 52W Low
- $12.28
- 50D MA
- $21.15
- 200D MA
- $16.98
- Beta
- -0.34
- Avg Volume
- 247
Get TickerSpark's AI analysis on SPHDF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SPHDF Coverage
We haven't published any research on SPHDF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SPHDF Report →